KRAS and non-small cell lung carcinoma: We report the first intergroup study of KRAS patients in the Asian race with a complete follow-up process from the initial diagnosis stage, showing the difference in therapeutic effect and prognosis of advanced KRAS-mutant NSCLC in three first-line treatments under stratified factors according to molecular profiles.